Researchers found that about 12 percent to 15 percent of breast cancer patients carry multiple mutations in the gene, 95 percent of which are double mutations.
The company's SpliceCore platform maps patient RNA sequencing data to a collection of over 5 million alternative splicing errors to pinpoint ones that cause disease.
The company said it has seen progress in efforts to get FDA approval for its tissue and liquid biopsy tests as data continues to accumulate for pan-cancer utility.
The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.
Though some experts prefer the comprehensive nature of whole-genome sequencing, others find whole-exome sequencing or targeted exome panels to be more useful.
Combined DNA/RNA-seq efforts in various settings could lead to new ways of treating kids with drugs meant for adults or to the development of new therapies.
Tissue-agnostic drug development approaches have their own set of scientific and financial considerations, but some drugmakers are taking on those challenges.
